Skip to main content
SpringerLink
Log in

In response to the study “a randomized trial of medical cannabis in patients with stage for cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient’s satisfaction” by Dr. Zylla and colleagues

  • Letter to the Editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

The Original Article was published on 04 June 2021

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Zylla DM, Eklund J, Gilmore G et al (2021) A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer 29(12):7471–7478

    Article  Google Scholar 

  2. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39(2):167–179

    Article  Google Scholar 

  3. Portenoy RK, Ganae-Motan ED, Allende S et al (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13(5):438–449

    Article  CAS  Google Scholar 

  4. Fallon MT, Albert Lux E, McQuade R et al (2017) Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain 11(3):119–133

    Article  Google Scholar 

  5. Lichtman AH, Lux EA, McQuade R et al (2018) Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage 55(2):179-188 e171

    Article  Google Scholar 

  6. Maguire DR, France CP (2018) Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure. Psychopharmacology 235(8):2357–2365

    Article  CAS  Google Scholar 

  7. Maguire DR, France CP (2018) Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: impact of drug and fixed-dose ratio. Eur J Pharmacol 819:217–224

    Article  CAS  Google Scholar 

  8. Maguire DR, France CP (2016) Additive antinociceptive effects of mixtures of the kappa-opioid receptor agonist spiradoline and the cannabinoid receptor agonist CP55940 in rats. Behav Pharmacol 27(1):69–72

    Article  CAS  Google Scholar 

  9. Maguire DR, France CP (2014) Impact of efficacy at the mu-opioid receptor on antinociceptive effects of combinations of mu-opioid receptor agonists and cannabinoid receptor agonists. J Pharmacol Exp Ther 351(2):383–389

    Article  Google Scholar 

  10. Ioannidis JPA (2017) The reproducibility wars: successful, unsuccessful, uninterpretable, exact, conceptual, triangulated, contested replication. Clin Chem 63(5):943–945

    Article  CAS  Google Scholar 

  11. Ioannidis JPA (2018) Why replication has more scientific value than original discovery. Behav Brain Sci 41:e137

    Article  Google Scholar 

  12. Boutron I, Dutton S, Ravaud P, Altman DG (2010) Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303(20):2058–2064

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Director of Palliative Care Research, Geisinger Health System, 100 North Academy Ave., Danville, PA, 17821, USA

    Mellar P. Davis

Authors
  1. Mellar P. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mellar P. Davis.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davis, M.P. In response to the study “a randomized trial of medical cannabis in patients with stage for cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient’s satisfaction” by Dr. Zylla and colleagues. Support Care Cancer 30, 4579–4580 (2022). https://doi.org/10.1007/s00520-021-06768-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-021-06768-8

Search

Navigation